Surrozen raises $33M in series A

Regenerative therapy newco Surrozen Inc. (South San Francisco, Calif.) raised $33 million in a series A round led by The Column Group. Acting CEO and Column Group Managing Director Tim Kutzkey told BioCentury that Stanford University and individual investors also participated.

Kutzkey said Surrozen hopes to use a targeted approach to tune Wnt signaling for use in regenerative therapies, using technology with which it can create "surrogate" Wnt proteins with enhanced solubility. Stanford's K. Christopher Garcia and Claudia Janda, who developed the technology, are among Surrozen's co-founders...